secwatch.observer — SEC 8-K summary
======================================

Issuer:     Incannex Healthcare Inc. (IXHL)
CIK:        0001873875
Form:       8-K
Filed at:   2026-05-14T11:30:31+00:00
Accession:  0001213900-26-056227
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incannex commences DReAMzz study of IHL-42X for obstructive sleep apnea
-----------------------------------------------------------------------

- All 14 clinical trial sites identified; site contracting underway; import/export permits secured.
- Study is a crossover dose optimization to de-risk Phase III pathway for IHL-42X.
- Previously reported Phase II RePOSA showed statistically significant AHI reductions and improved oxygenation.
- FDA granted Fast Track designation for IHL-42X in OSA.
- Manufacturing of clinical trial supply completed; global distribution partner onboarded.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873875/000121390026056227/0001213900-26-056227-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873875/000121390026056227/ea0290292-8k_incannex.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-056227

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer